- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04151485
The Effect of the Mind/Body Program for Fertility, Hungarian Version, on Well-Being and Assisted Reproduction Outcomes
The Effect of the Mind/Body Program for Fertility, Hungarian Version, on Psychological Well-Being and Assisted Reproduction Technology (ART) Outcomes: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Involuntary childlessness imposes significant psychological burden on those affected, particularly those involved in assisted reproductive technology (ART). The reduction of psychological distress has been shown to improve the quality of life of those affected and to possibly increase chances of pregnancy. While in more developed countries psychological support is largely available in routine fertility care, it is not yet part of the Hungarian ART protocol.
In this study, the effects of a psychosocial intervention, namely, the Hungarian version of the Mind/Body Program for Fertility (Domar et al., 2011), will be tested on the psychological well-being and ART outcomes of women in reproductive treatment, in a randomized controlled pre-post design.
For this purpose, women in ART treatment will fill in screening questionnaires (on depression, anxiety, stress, etc.), and moderate to high scorers will be randomized into an intervention (Mind/Body) group (N=70) and a comparison intervention (Fertility Support) group (N=70), lasting for 10 weeks each, before and/or during an ART cycle. Both interventions will be delivered by the same clinical psychologist, listed as central contact person below, officially trained in the Mind/Body Program for Fertility by Dr. Alice Domar at Boston IVF, Waltham, Massachusetts. A smartphone application for rating subjective stress levels twice a day, from the start of the stimulation to the day of the pregnancy test, will also be administered. Additionally, whole-night sleep EEGs will be recorded.
Medical data (such as diagnosis, hormone levels, previous treatment cycles, etc.) and sociodemographic (such as age, education, etc.) and psychological variables (such as personality traits, chronotype, intelligence, etc.) as potential moderators, as well as ART outcomes will be reported. Data of respondents willing to fill in pre- and post-questionnaires but 1) not motivated to take part in the study, or 2) motivated to take part in the study, but not able to make it, will be registered but excluded from statistical analysis comparing RCT results.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Budapest, Hungary, 1082
- Assisted Reproduction Center of the Department of Obstetrics and Gynecology at Semmelweis University
-
Budapest, Hungary, 1089
- Institute of Behavioral Sciences at Semmelweis University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: All women awaiting or undergoing infertility treatment (insemination, in vitro fertilization or intracytoplasmic sperm injection) at the Assisted Reproduction Center of the Department of Obstetrics and Gynecology at Semmelweis University, Budapest, who:
- give informed consent to participating in the study
- have sufficient knowledge of the Hungarian language
Exclusion Criteria:
- active psychotic episode
- severe depression or other major psychiatric diagnoses
- substance abuse
- eating disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mind/Body Group
All persons allocated to the intervention group will take part in a 10-week Mind/Body skills development fertility program parallel with fertility workup and treatment.
|
see Arm Description
|
|
Active Comparator: Support Group
All persons allocated to the comparison intervention group will take part in a 10-week fertility support program parallel with fertility workup and treatment.
|
see Arm Description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change from baseline in results on the Fertility Quality of Life tool
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the Fertility Quality of Life (FertiQoL) Core Scale, subscales and Treatment Module
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the SCREENIVF tool
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the SCREENIVF tool and its subscales
|
through study completion, an average of 2 years
|
|
Clinical pregnancy
Time Frame: through study completion, an average of 2 years
|
Rate of clinical pregnancies at post-measurement
|
through study completion, an average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change from baseline on a Likert scale measuring strength of intention to continue treatment
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline on a 10-point Likert scale measuring strength of intention to continue treatment (if first ART cycle not successful) to post-measurement
|
through study completion, an average of 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change from baseline in results on the Beck Depression Inventory
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 21-item Beck Depression Inventory (BDI), with special attention to category change (e.g. from moderate to mild depression level, from mild to no depression)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the World Health Organisation-Five Well-Being Index
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 5-item World Health Organisation-Five Well-Being Index (WHO-5)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Spielberger State-Trait Anxiety Inventory
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the State and Trait subscales of the Spielberger State Trait Anxiety Inventory (STAI)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Short Stress Scale
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 26-item Short Stress Scale (SSS)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Perceived Stress Scale
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 10-item Perceived Stress Scale (PSS-10)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Life Meaning subscale of the Brief Stress and Coping Inventory
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 7-item Life Meaning subscale of the Brief Stress and Coping Inventory (BSCI-LM)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Awareness of Mind-Body Integration and the Trusting Body Sensations subscales of the Multidimensional Assessment of Interoceptive Awareness
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 12-item Awareness of Mind-Body Integration and the 3-item Trusting Body Sensations subscales of the Multidimensional Assessment of Interoceptive Awareness (MAIA)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Fertility Problem Stress Scales and the Coping Strategy Scales of the Copenhagen Multi-centre Psychosocial Infertility study questionnaire
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 14-item Fertility Problem Stress Scales and the 19-item Coping Strategy Scales of the Copenhagen Multi-centre Psychosocial Infertility (COMPI) study questionnaire
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Sexual Concerns subscale of the Fertility Problem Inventory
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 8-item Sexual Concerns subscale of the Fertility Problem Inventory
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Relationship Assessment Scale
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 7-item Relationship Assessment Scale (RAS)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Pittsburgh Sleep Quality Index
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the Pittsburgh Sleep Quality Index (PSQI)
|
through study completion, an average of 2 years
|
|
Mean change from baseline in results on the Athens Insomnia Scale
Time Frame: through study completion, an average of 2 years
|
Mean change from baseline in results on the 8-item Athens Insomnia Scale (AIS)
|
through study completion, an average of 2 years
|
|
Mean results on a smartphone-based Likert-scale rating momentary stress
Time Frame: through study completion, an average of 2 years
|
Mean results on the StressFlash smartphone-based Likert-scale rating momentary stress
|
through study completion, an average of 2 years
|
|
Number of oocytes retrieved
Time Frame: through study completion, an average of 2 years
|
Number of oocytes retrieved at transvaginal oocyte retrieval (TVOR)
|
through study completion, an average of 2 years
|
|
Number of oocytes fertilized
Time Frame: through study completion, an average of 2 years
|
Number of oocytes fertilized via IVF/ICSI
|
through study completion, an average of 2 years
|
|
Number of embryos transferred
Time Frame: through study completion, an average of 2 years
|
Number of embryos transferred at embryo transfer (ET)
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: György Purebl, PhD Ass.Prof, Institute of Behavioural Sciences, Semmelweis University, Budapest
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 83/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Female
-
Yuzuncu Yil UniversityCompletedUnexplained Infertility | Female Infertility | Anovulatory InfertilityTurkey (Türkiye)
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
BEYOND GENOMiX SA, AG, LtdPraxis für Akupunktur und Chinesische Arzneimittel; Fertisuisse Ltd, SA, AGRecruitingInfertility Unexplained | Infertility (IVF Patients) | Idiopathic Infertility | Infertility Female | Infertility Assisted Reproductive TechnologySwitzerland
-
Newlife Fertility CentreRecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, NonimplantationCanada
-
Sapientiae InstituteTerminated
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Cairo UniversityCompleted
Clinical Trials on Mind/Body Program for Fertility (Domar et al., 2011)
-
Beth Israel Deaconess Medical CenterCompleted
-
Zealand University HospitalUniversity of Copenhagen; Steno Diabetes Center Copenhagen; Holbaek SygehusRecruitingCardiovascular Diseases | Obesity | Metabolic Disease | NAFLD, Non-alcoholic Fatty Liver DiseaseDenmark
-
University of UtahTerminated
-
Charite University, Berlin, GermanyCompletedHealthy | Alcohol Use Disorder (Mild vs. Moderate to Heavy)Germany
-
Massachusetts General HospitalCenters for Disease Control and PreventionCompletedDepressionUnited States
-
Institut de Cancérologie de LorraineRecruitingNon Metastatic Breast CancerFrance